This scientific talk presents how the iLite Reporter Cell Platform can be used for assay development within the field of AAV therapies and how iLite cell lines can be engineered for specific and general assays.
The analytical demands of cell and gene therapies can be extremely challenging throughout the development phases. The use of bioassays facilitates the different developmental phases as they can be used to determine key parameters including vector potency, product identity, or determination/titration of neutralizing antibodies.
Here, we present different strategies for the development of reliable bioassays for specific or more global use by showcasing a selection of our engineered iLite cells.
Learning objectives
- How can a bioassay be developed for use in the development of AAV therapies?
- What characteristics are important to consider when developing assays for specific therapies?
- Which advantages does the iLite technology present for gene therapy bioassays?
- How can neutralizing antibodies against AAV vectors be detected using bioassays?
TIME: 14 min
